ABSTRACT -Fucoxanthin (FX), a xanthophyll derivative, is an orange-colored pigment present in edible brown algae. As a part of safety evaluation, single and repeated oral dose toxicity study of FX was ICR mice at doses of 1,000 and 2,000 mg/kg. In a repeated doses study, FX at doses of 500 and 1,000 appearance were observed. In the repeated doses study, histological observation revealed no abnormal -ly increased total cholesterol concentrations were shown by plasma biochemical analyses in all FX-treated groups. Although total bilirubin concentrations were increased by FX, it was established that presence of fucoxanthinol, a major metabolite of FX, interfered with bilirubin determination in plasma. To further ascertain the safety of FX, the mechanism by which FX induces hypercholesterolemia in mice and species differences in the induction of hypercholesterolemia should be elucidated.
INTRODUCTION
According to the survey in 2005 by the World Health Organization (WHO, 2006) , globally 1.6 billion people (over 15 years of age) are overweight (body mass index;
Recently, there is a rapid increase in incidence of obesity not only in the developed countries such as European countries and USA but also in the developing countries, and it is estimated that the number of overweight -lion in 2015 (WHO, 2006) . WHO reported that the reasons for increased incidence of obesity are presumably attributable to the global tendencies toward reduced magnitude of exercise and physical activity, increased intake of high fat, high sugar and high calorie diet with reduced amount of vitamins and minerals. In Japan, according to the survey for national health and nutrition conducted by the Ministry of Health, Labor and Welfare, the incidences 2006).
To prevent life-style-related diseases, it is important to rectify the badly balanced nutritional conditions due to imbalanced habitual diet. Attention has also been focused on functional ingredients in foods, which may be useful for the prevention and treatment of life-style-related diseases. One of the typical examples of such functional ingredient is fucoxanthin (FX) (Fig. 1) . FX, a xanthophyll derivative, is an orange-colored pigment and is ( ). It has been reported that FX shows antiobesity effect through uncoupling protein (UCP)1 expression in white adipose tissue (WAT) in KKAy mice, an animal model of type 2 diabetes with obesity (Maeda et al., 2005) . When FX is orally administered in mice, it is metabolized to fucoxanthinol (FXOH) (Fig. 1) , which is further converted into amarouciaxanthin A (Asai et al., et al., 2002) . FX as well as its metabolite FXOH have been shown to reduce the expression of per-L1 preadipocytes, which in turn resulted in the inhibited differentiation to mature adipocytes (Maeda et al., 2006) , suggesting that FX also acts as an inhibitor against adipocyte maturation in addition to being a stimulator for UCP1 expression in WAT. Beside the antiobesity effect, it has been reported that dietary FX or FXOH increases the amount of docosahexaenoic acid (DHA) in the liver of KKAy mice (Tsukui et al., ly important benefits (Fischer et al., 2008; Harris et al., 2008; Kelley et al., 2008; Lindmark and Clough et al In vitro and in vivo studies further revealed that FXOH and/or FX possesses antioxidant activity (Sachindra et al -ity against different kinds of cancer cells (Das et al., 2008; Ishikawa et al., 2008; Konishi et al., 2006; Satomi (Shiratori et al., 2005) .
As described above, there are many reports on FX in terms of its effect on physiological and pharmacological implications, while few studies have been conducted on and sea tangle have been eaten in Japan for a long time, safety evaluation of FX should be conducted if concentrated FX is to be applied for dietary supplements and/ or as functional foods. Therefore, single oral dose and repeated oral dose studies on purified FX (purity was safety evaluation.
MATERIALS AND METHODS
The studies reported in this work have been conduced in accordance with the guidelines for animal experiment and animal care adopted by Sunny Health Holdings Co., Ltd. (Nagano, Japan).
Test substances
FX was purified according to the method described previously (Maeda et al containing FX were obtained from commercial dried brown seaweed using acetone extracto silica gel column chromatography twice with n-hexas checked by high performance liquid chromatography of chlorophyll fraction was observed during the process of silica gel column chromatography, the likely major component of impurities is chlorophyll. FX was suspended in --administered with FX suspension at a volume of 10 ml/kg (doses of FX were 1,000 and 2,000 mg/kg in single dose study, and 500 and 1,000 mg/kg in repeated dose study). Control animals received the same amount of vehicle used as a foodstuff rather than a pharmaceutical. Therefore high doses of 500 and 1,000 mg/kg/day were set in repeated dose study to check if FX causes grave toxicological problems as a foodstuff. FXOH was prepared by hydrolysis of FX with lipase as described by Tsukui et al of taurocholic acid sodium salt were dissolved in methanol, and the solvent was dried under nitrogen. Then 20 g of porcine pancreas lipase, type II (Sigma, St. Louis, MO, USA) dissolved in 1,000 ml of 0.1 M potassium phostaurocholic acid followed by sonication. After incubation methanol/diethyl ether (1:1, v/v), and the diethyl ether phase containing FXOH was separated. FXOH was furacetone/n-hexane (1:1, v/v). The purity of FXOH was
Animals
Five-week-old male and female ICR mice were purchased from Clea Japan Inc. (Tokyo, Japan), and used after acclimatization for 1 week. During acclimatization and experimental periods, animals were kept under free access to food pellets (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water. Animals were housed at Single oral dose study -ed to each group consisting of 10 animals. After starvaat doses of 1,000 and 2,000 mg/kg or its vehicle alone. Gross appearances of animals were observed immediately and after 6 hr of the administration and thereafter once dislocation under ether anesthesia for macroscopic observation.
Repeated oral doses study for 30 days
cated to each group consisting of 10 animals. Animals were orally administered with FX at doses of 500 and appearances of animals were observed every day and feed intakes were measured every two days. On the following day of the last administration, blood samples were taken from the cervical vein of animals starved overnight, under macroscopy was conducted for abdominal tissues, and liver, spleen, kidney, and gonadal tissues. The tissues were -toxylin and eosin for microscopy. Concentrations of total protein, albumin, glucose, triglyceride, total cholesterol, phospholipids, non-esterified fatty acid (NEFA), blood urea nitrogen (BUN), uric acid, creatinine, total bilirubin, aspartate amino transferase (AST), alanine transamiand magnesium in plasma were measured by using a multi-channel automatic analyzer (HITACHI Automatic Anaof sodium, potassium and chloride in plasma were measured by using an EA06R automated electrolyte analyzer (A & T, Tokyo, Japan).
Repeated oral dose study for 7 days
increases in total bilirubin concentrations were found in the FX groups. End point of vanadic acid oxidation method for bilirubin determination used in the study is the -metabolite of FX in the circulation (Asai et al Sugawara et al., 2002) . Therefore, we postulated that plasma FXOH interfered with bilirubin determination. To to compare plasma concentrations of total bilirubin to be measured by two methods. Regarding other parameters than bilirubin, end points for determinations are not the Thirty male animals were allocated to each group consisting of 5 animals. Animals were orally administered with FX at doses of 500 and 1,000 mg/kg or its vehicle -istration, blood samples were taken from the cervical vein of animals starved overnight, under ether anesthesia. Plasma concentrations of total bilirubin were measured by using two types of assay kits. One was E-HA test Wako (Wako Pure Chemicals, Osaka, Japan) based on and the other was QuantiChrom TM Bilirubin Assay Kit (BioAssay Systems, Hayward, CA, USA) based on the 1981).
Statistical analyses
trol group were assessed by Dunnet's multiple comparison test.
RESULTS

Single oral dose study
No mortality and no abnormalities in gross appearance of the animals were observed during the experimental period. Body weight gain in the male and female experimental groups (FX 1,000 mg/kg and FX 2,000 mg/kg groups) was similar to that in the corresponding control groups and no significant (p > 0.05) differences were found (data not shown). No abnormal findings 50 ) of FX in mice is more than 2,000 mg/kg.
Repeated oral dose study for 30 days
No mortality and no abnormalities in gross appearance of the animals were observed during the experimental period. Fecal color of the animals administered with FX suspension was orange-like, which was presumably derived from orally administered FX. Fig. 2 shows time course changes in body weight of experimental animals. In both the male and female animals, body weight gain in FX 500 mg/kg and FX 1,000 mg/kg groups was similar to --ferences were also found in feed intake (data not shown).
Plasma biochemical parameters reflecting liver and kidney functions are summarized in Table 1 . In both the male and female animals, plasma total bilirubin concentrations in FX 500 mg/kg and FX 1,000 mg/kg groups -responding control groups. Although plasma albumin concentrations in the male FX 500 mg/kg group and the lower than those in the corresponding control groups, the differences were very small and the values in the experimental groups were within the normal range. Plasma BUN concentration in the female FX 500 mg/kg group -trol group, but, as is the case with albumin, the value was found in the other parameters.
Plasma concentrations of glucose, lipids and minerals are summarized in Table 2 . All of the FX groups showed -lesterol and phospholipids than those in the corresponding control groups. Inorganic phosphorus concentrations in the male FX 500 mg/kg and FX 1,000 mg/kg groups -sponding control group.
Macroscopic observation showed no abnormalities in the abdominal tissues of all of the FX groups except that the color of the adipose tissues was orange-like. Relative weights of liver, kidney, spleen and gonadal tissues than those in the corresponding control groups. Relative prostate gland weight in the male FX 500 mg/kg group and relative spleen weight in the female FX 1,000 mg/kg the corresponding control groups. However, histological observations revealed no abnormalities in the liver, kidney, spleen and gonadal tissues in all of the FX groups as compared with those in the corresponding control groups, indicating that FX has no adverse effects on these tissues.
Repeated oral dose study for 7 days
od and Jendrassik-Grof method were applied for bilirubin -ured by the vanadic acid oxidation method is shown in FX groups measured by the former method were prominently higher than those in the control group, while those those in the control group.
DISCUSSION
No mortality of mice was observed in the single dose study, indicating that LD 50 of FX in mice is more than 2,000 mg/kg. In addition, since repeated administration mortality, no abnormalities in gross appearance of the -vations, it is suggested that FX is a safe compound for -er weight by the administration of FX, since hypertrophy of hepatocytes could not be observed by light microscopy, the reason for this cannot be explained with present data. One of the possibilities is induction of cytochromeysis in future studies. In addition, further study by transmittance electron microscopy is needed to observe subcellular structural changes of hepatocytes.
As for plasma biochemical parameters in the repeated doses study, plasma total bilirubin concentrations measured by the vanadic acid oxidation method in FX groups were significantly higher than those in the correspond- ing control groups. Since parameters for liver function -vation for liver sections showed no abnormal changes by FX, we speculated that the increased level of total bilirubin by FX is possibly artifact caused by substances that existed in the plasma. As described earlier, we postulated that FXOH interfered with bilirubin determination, determination by the vanadic acid oxidation method that Indeed, in our preliminary study in which plasma concentrations of FXOH were determined after oral FX at single doses of 500 and 1,000 mg/kg, FXOH was detected administration (data not shown). When FXOH was add- 25 ± 8 ± 6 29 ± 8 25 ± ± 6 ± 6 ALP(U/l) 196 ± ± 226 ± ± ± 259 ± 50 0.9 ± 1.2 ± 1.1 0.9 ± 1.8 Urea nitrogen (mg/dl) 21.6 ± 2.8 ± ± 6.6 20.1 ± 25.5 ± 5.1 * ± Uric acid (mg/l) ± 0.95 ± 0.19 1.12 ± 0.95 ± 0.18 1.08 ± 0.96 ± 0.18 Creatinine (mg/dl) 0.09 ± 0.02 0.09 ± 0.02 0.11 ± 0.02 0.09 ± 0.02 0.11 ± 0.10 ± 0.02
Each value represents the mean and standard deviation of 10 mice. * ** 2.06 ± 0.21 2.10 ± 2.05 ± 2.21 ± ± 0.21 2.02 ± 0.12 Sodium (mmol L -1 ) ± 1.0 151.8 ± ± 0.9 151.9 ± ± 1.6 ± 2.8 Potassium (mM) 6.50 ± 1.25 ± 6.89 ± ± 1.02 ± 6.51 ± 0.95 Chloride (mM) ± 1.8 ± ± 2.5 115.5 ± 2.2 115.6 ± 2.2 ± 2.9
Each value represents the mean and standard deviation of 10 mice. * ** ed to pooled mouse plasma at concentrations of 0.5 and vanadic acid oxidation method were increased by more than 10-fold, but not by Jendrassik-Grof method, where plasma concentrations of total bilirubin in both of the FX groups measured by the vanadic acid oxidation method were prominently higher than that in the control group, while those by Jendrassik-Grof method were not significantly different from that in the control group. From these, it is suggested that FXOH present in the plasma interfered with bilirubin determination when measured by the vanadic acid oxidation method. Further examination of the relationship between plasma concentration of FXOH and its possible interference with bilirubin determination needs to be carried out. Regarding the difference in total bilirubin concentrations between two control groups (vanadic oxidation method and Jendrassik-Grof method), although the reason for the difference is not clear at present, a similar tendency was reported in the rat studies. That is, total bilirubin concentration measured by Jendrassik-Grof method was much higher than that measured by the vanadic acid oxidation method (Sirota et al., 2008; Yamaguchi et al., 2008) . In addition to total bilirubin concentrations, all of the FX groups showed significantly higher total cholesterol concentrations than those in the corresponding control groups. It was reported that 28 days-repeated oral administration of FX at doses of 10 and 50 mg/kg to male and and 1.9-2.2 fold, respectively . In days oral administration of FX at doses of 500 and 1,000 mg/kg, which were much higher than those in the rat study, resulted in increased total cholesterol concentrations to the same degree as in the rat study. Therefore, it is speculated that FX increases total cholesterol concentrations in rodents to the maximal level of approximately 2-fold increase even at higher doses of FX. Since HDLcholesterol concentrations also increased in the rat study as is the case with the total cholesterol, further examination is required to assess whether FX at higher doses increases HDL cholesterol level in mice. Regarding other carotenoids, it has been reported that rats fed with diets -cantly increased plasma total cholesterol levels to 1.8 fold -icantly increased serum total cholesterol levels in a dosedependent manner (Kuroiwa et al., 2006) , suggesting that some sort of carotenoids may have an ability to increase circulating cholesterol level in rodents as a common feamechanisms by which FX and other xanthophylls increas- As for slight but significant increases in inorganic phosphorous concentrations in the male FX groups, histological observation of kidney showed no abnormalities, and calcium concentrations were not increased, the increased level of inorganic phosphorous found in this study is not grave toxicological problem.
